New York, U.S. | Xinhua | U.S. pharmaceutical company Pfizer Inc. on Tuesday presented weaker-than-expected operating guidance for 2022 leading to material loss of its stock price. Pfizer expects to realize 98 billion to 102 billion U.S. dollars of revenues in 2022 and the mid-point of the guidance range represents a …
Read More »U.S. orders more pills from Pfizer amid Omicron dominance in 3rd year of pandemic
New York, U.S. | Xinhua | Omicron was officially announced on Tuesday as the absolutely dominant variant of COVID-19 in the United States, as the country is entering the third year of the pandemic, with more curing pills ordered from Pfizer while the federal government’s policies criticized as murky. OMICRON DOMINANCE …
Read More »U.S. FDA authorizes first oral antiviral for COVID-19 treatment
Washington, U.S. | Xinhua | The U.S. Food and Drug Administration on Wednesday authorized Pfizer’s oral antiviral tablets for the treatment of mild-to-moderate COVID-19, the first pill approved for COVID-19 treatment in the country. The pill, called Paxlovid, is authorized for use in adults and pediatric patients 12 years of age …
Read More »EMA recommends emergency use of Pfizer COVID-19 pill
The Hague, Netherlands | Xinhua | The European Medicines Agency (EMA) on Thursday issued advice on the emergency use of Pfizer’s COVID-19 pill called Paxlovid. The European Union (EU) drug regulator said the medicine, which is not yet authorized in the EU, can be used to treat adults with COVID-19 who …
Read More »